drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
An intravenous antibody–drug conjugate (ADC) targeting B7-H3 (CD276), linked to a cytotoxic topoisomerase I inhibitor payload. After binding B7-H3 on tumor cells, it is internalized and releases the payload to inhibit topoisomerase I, causing DNA damage and tumor cell death; dosed every 3 weeks in advanced solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Monoclonal antibody targeting B7-H3 (CD276) that is internalized upon binding and releases a linked topoisomerase I inhibitor payload inside tumor cells, inhibiting topo I, inducing DNA damage, and causing tumor cell death.
drug_name
7MW3711
nct_id_drug_ref
NCT06008366